Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Wandel

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
European Heart Journal|November 6, 2009
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-studyPeter Barlis, Evelyn Regar, Patrick W Serruys, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
Journal of the American College of Cardiology|September 18, 2007
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trialMario Togni, Stéphanie Eber, Jeannette Widmer, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
Lancet (London, England)|September 4, 2008
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trialStephan Windecker, Patrick W Serruys, Simon Wandel, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
Lancet (London, England)|September 18, 2007
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisChristoph Stettler, Simon Wandel, Sabin Allemann, et al.
BMJ (Clinical Research Ed.)|September 2, 2008
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysisChristoph Stettler, Sabin Allemann, Simon Wandel, et al.
Journal of the American Heart Association|June 21, 2024
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic SubstudyNatasha L Patel-Murray, Luqing Zhang, Brian L Claggett, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
European Heart Journal|November 6, 2009
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-studyPeter Barlis, Evelyn Regar, Patrick W Serruys, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
Journal of the American College of Cardiology|September 18, 2007
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trialMario Togni, Stéphanie Eber, Jeannette Widmer, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
Lancet (London, England)|September 4, 2008
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trialStephan Windecker, Patrick W Serruys, Simon Wandel, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
Lancet (London, England)|September 18, 2007
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisChristoph Stettler, Simon Wandel, Sabin Allemann, et al.
BMJ (Clinical Research Ed.)|September 2, 2008
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysisChristoph Stettler, Sabin Allemann, Simon Wandel, et al.
Journal of the American Heart Association|June 21, 2024
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic SubstudyNatasha L Patel-Murray, Luqing Zhang, Brian L Claggett, et al.
Pageof 4